A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2009
12/10/2009	US20090304605 Substituted Aminothiazole Prodrugs of Compounds with Anti-HCV Activity
12/10/2009	US20090304602 Nutritional supplement
12/10/2009	US20090304590 Therapeutic compositions and methods
12/10/2009	US20090304584 Conjugates comprising a gaba- or glycine compound, pharmaceutical compositions and combinations thereof and their use in treating cns disorders
12/10/2009	US20090304583 Pathological tissue detection and treatment employing targeted benzoindole optical agents
12/10/2009	US20090304577 Peptides for Treatment and Diagnosis of Autoimmune Disease
12/10/2009	US20090304575 In vitro method for identifying compounds for cancer therapy
12/10/2009	DE19612966B4 MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren MDCK cells and methods for the propagation of influenza virus
12/10/2009	DE10222561B4 Protektive Lösung zur Verhinderung von Ischämieschäden Protective solution for preventing ischemic damage
12/10/2009	DE102009012465A1 Pharmazeutische Zusammensetzung zur Prophylaxe und Behandlung der Arteriosklerose, sowie zur Schmerzbekämpfung und zur Entzündungshemmung A pharmaceutical composition for the prophylaxis and treatment of atherosclerosis, as well as pain relief and inflammation
12/10/2009	DE102008027387A1 Use of flubendazole for producing a medicine, where the veterinary medicine is useful for combating gill worms or intestinal parasitic worm in fishes and contains dimethyl sulfoxide and flubendazole as active substances
12/10/2009	DE102008027361A1 Composition, useful e.g. for the chemosensibilizing and simultaneous apoptosis induction of multidrug resistance of tumor cells and bacteria, comprises substituted disiloxane compound in combination with benzoxazole derivatives
12/10/2009	DE102008027331A1 Verwendung von Indol-3-carbonsäureestern zur Hemmung der mikrosomalen Prostaglandin E2 Synthase The use of indole-3-carboxylic acid esters to inhibit the microsomal prostaglandin E2 synthase
12/10/2009	DE102008019838A1 Neue Arylsulfonylglycin-Derivate, deren Herstellung und deren Verwendung als Arzneimittel Arylsulfonylglycin new derivatives, their preparation and their use as medicaments
12/10/2009	CA2764456A1 Oligonucleotide duplexes comprising dna-like and rna-like nucleotides and uses thereof
12/10/2009	CA2758016A1 Novel modulators of protein kinase signaling
12/10/2009	CA2727054A1 Method for inhibiting the growth of bacteria
12/10/2009	CA2727018A1 Anthraquinones and analogs from rhuem palmatum for treatment of estrogen receptor beta-mediated conditions
12/10/2009	CA2726987A1 Stat3 inhibitors
12/10/2009	CA2726985A1 Small molecule inhibitors for the treatment or prevention of dengue virus infection
12/10/2009	CA2726944A1 Acne treatment compositions comprising nanosilver and uses
12/10/2009	CA2726939A1 4,6-diphenylpyrid-2-ones against cancer
12/10/2009	CA2726925A1 Isoxazole derivatives and their use as metabotropic glutamate receptor potentiators
12/10/2009	CA2726907A1 Dihydro-iso ca-4 and analogues: potent cytotoxics, inhibitors of tubulin polymerization
12/10/2009	CA2726890A1 Creamy o/w emulsion composition and production process thereof
12/10/2009	CA2726885A1 Sirna of human osteopontin
12/10/2009	CA2726883A1 New terpenes and macrocycles
12/10/2009	CA2726878A1 Novel treatments
12/10/2009	CA2726874A1 Novel treatments
12/10/2009	CA2726872A1 Compositions for the treatment of disorders of the upper respiratory tract and influenza syndromes
12/10/2009	CA2726855A1 C-ring-substituted pregn-4-ene-21,17-carbolactones, and pharmaceutical products comprising the same
12/10/2009	CA2726833A1 Pharmaceutical compositions for treatment of parkinson's disease
12/10/2009	CA2726793A1 Pulsatile release of valsartan
12/10/2009	CA2726763A1 Controlled release copolymer formulation with improved release kinetics
12/10/2009	CA2726755A1 Selenophene and selenazole carboxylic acid derivatives
12/10/2009	CA2726742A1 Hiv integrase inhibitors from pyridoxine
12/10/2009	CA2726704A1 Pharmaceutical compositions containing a crystalline form of posaconazole
12/10/2009	CA2726673A1 Alpha helix mimetics and methods relating thereto
12/10/2009	CA2726662A1 A method for increasing bone density and/or reducing any osteochondral defects in an animal and a composition including vitamin k
12/10/2009	CA2726648A1 Pharmaceutical dosage form for immediate release of an indolinone derivative
12/10/2009	CA2726646A1 New compounds vii
12/10/2009	CA2726644A1 Pharmaceutical combination
12/10/2009	CA2726610A1 Sulfonamide compounds and use thereof
12/10/2009	CA2726588A1 Compounds and methods for treating inflammatory and fibrotic disorders
12/10/2009	CA2726579A1 Novel uracil compound or salt thereof having human deoxyuridine triphosphatase inhibitory activity
12/10/2009	CA2726554A1 Macrocyclic urea and sulfamide derivatives as inhibitors of tafia
12/10/2009	CA2726537A1 8-hydroxyquinoline derivatives for the treatment of hematological malignancies
12/10/2009	CA2726472A1 Solid pharmaceutical formulations comprising bibw 2992
12/10/2009	CA2726449A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
12/10/2009	CA2726442A1 Medicaments and methods for inhibition of scarring
12/10/2009	CA2726441A1 New pyridine derivatives as leptin receptor modulator mimetics
12/10/2009	CA2726377A1 Aldosterone induced vascular elastin production
12/10/2009	CA2726364A1 6-substituted estradiol derivatives and methods of use
12/10/2009	CA2726358A1 Inhibitors of akt activity
12/10/2009	CA2726317A1 Inhibitors of akt activity
12/10/2009	CA2726270A1 Small molecule leptin receptor modulators
12/10/2009	CA2726267A1 Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative
12/10/2009	CA2726258A1 Anti-tumoural effects of cannabinoid combinations
12/10/2009	CA2726257A1 Cannabinoids in combination with non-cannabinoid chemotherapeutic agents (e.g. serm or alkylating agents)
12/10/2009	CA2726244A1 Dpp-iv inhibitors for use in the treatment of nafld
12/10/2009	CA2725749A1 Novel compounds, pharmaceutical compositions containing same, and methods of use for same
12/10/2009	CA2725742A1 3- or 4-substituted piperidine compounds
12/10/2009	CA2725740A1 3-substituted propanamine compounds
12/10/2009	CA2725689A1 Thiazolo [5,4-b] pyridine and oxazolo [5,4-b] pyridine derivatives as antibacterial agents
12/10/2009	CA2725688A1 A transdermal drug delivery device
12/10/2009	CA2725616A1 [4-(1-amino-ethyl) -cyclohexyl] -methyl-amine and [6-(1-amino-ethyl) -tetrahydro- pyran-3-yl] -methyl-amine derivatives as antibacterials
12/10/2009	CA2725572A1 Heterocyclic urea derivatives and methods of use thereof
12/10/2009	CA2725568A1 Heterocyclic urea derivatives for the treatment of bacterial infections
12/10/2009	CA2725538A1 Indane derivatives as ampa receptor modulators
12/10/2009	CA2725470A1 Sofinicline (abt-894 ) for attention-deficit/hyperactivity disorder
12/10/2009	CA2725356A1 Treatment for neurological and mental disorders
12/10/2009	CA2725316A1 Novel isoxazole derivative
12/10/2009	CA2724905A1 Method of treating burns using avermectin compound
12/10/2009	CA2724882A1 Process for the synthesis of arformoterol
12/10/2009	CA2724878A1 3,4-dihydropyrimidine trpa1 antagonists
12/10/2009	CA2724678A1 Novel treatment of heart diseases
12/10/2009	CA2724376A1 Substituted quinazolines
12/10/2009	CA2724320A1 Solid states of aliskiren free base
12/10/2009	CA2724199A1 Promoting axon regeneration in the adult cns through control of protein translation
12/10/2009	CA2723871A1 Process for the synthesis of .gamma. -amino acids
12/10/2009	CA2723869A1 A process for the preparation of enantiomerically pure amines
12/10/2009	CA2723626A1 Compounds comprising a cyclobutoxy group
12/10/2009	CA2723029A1 Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent
12/10/2009	CA2722723A1 4-(aminomethyl)cyclohexanamine derivatives as calcium channel blockers
12/09/2009	EP2130923A2 Production of polyunsaturated fatty acids using novel cell treatment method
12/09/2009	EP2130920A2 Beta-like glycoprotein hormone polypeptide and heterodimer
12/09/2009	EP2130908A2 Retinoid compounds and their use
12/09/2009	EP2130834A1 Novel sulfonated sugar derivative, and use thereof for medicinal agent
12/09/2009	EP2130832A1 Copper organic complexes, use thereof as anti-tumour agent and protection of healthy tissue from ionised radiation
12/09/2009	EP2130831A1 CDC25 inhibitors
12/09/2009	EP2130830A1 Muscarinic receptor antagonists
12/09/2009	EP2130829A1 Novel hydroxyindole derivative
12/09/2009	EP2130828A1 Sulfonamide derivative
12/09/2009	EP2130826A1 Annulins A, B, C or analogs as indoleamine 2,3-dioxygenase (IDO) inhibitors for treatment of cancer
12/09/2009	EP2130825A1 N-substituted thiomorpholine derivatives as the inhibitors of dipeptidyl peptidase iv and the pharmaceutical uses thereof
12/09/2009	EP2130824A1 Composition for treating infectious diseases caused by helicobacter
12/09/2009	EP2130823A1 Compound that is a dual inhibitor of enzymes pde7 and/or pde4, pharmaceutical compositions and uses thereof
12/09/2009	EP2130822A1 2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between p53 and mdm2 proteins for use as anticancer agents
12/09/2009	EP2130820A1 Antipruritics
12/09/2009	EP2130819A2 Crystalline forms of atorvastatin magnesium

1 ... 2466 2467 2468 2469 2470 2471 2472 2473 2474 2475 2476 2477 2478 2479 2480 2481 2482 2483 2484 2485 2486 ... 7860